Status:
COMPLETED
L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels
Lead Sponsor:
Nicholas Kenyon
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
Conditions:
Asthma
Inflammation
Eligibility:
All Genders
19+ years
Phase:
PHASE2
Brief Summary
The major impact of this study will be to identify the adult severe asthma cohort that will benefit from supplemental L-arginine therapy. The investigators hypothesize that a subset of adult severe as...
Detailed Description
We hypothesize that a subset of adult severe asthma patients will respond to supplemental L-arginine and derive clinical benefit from the addition of this therapy to standard-of-care medications. We h...
Eligibility Criteria
Inclusion
- Adults \>18 yrs of age
- Diagnosis of severe asthma based on American Thoracic Society Workshop definition (Am J Respir Crit Care Med 2000; 162:2341)
- Active asthma medications of high dose inhaled corticosteroids plus long-acting beta agonist
- History of recent asthma exacerbations or Asthma control test score \< 20/25
Exclusion
- \<19 yrs of age
- Forced expiratory volume 1sec \<30% predicted
- Pregnant or nursing women
- Current smokers or smoking history \> 15 pack years
- Actively taking or known intolerance to L-arginine
Key Trial Info
Start Date :
August 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT01841281
Start Date
August 1 2013
End Date
December 1 2019
Last Update
April 21 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UC Davis CTSC Clinical Research Center
Sacramento, California, United States, 95817